Last reviewed · How we verify
KN035 plus Gemcitabine & oxaliplatin
KN035 is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with gemcitabine and oxaliplatin chemotherapy.
KN035 is a PD-L1 inhibitor that blocks the interaction between PD-L1 and PD-1/PD-L2, restoring anti-tumor immune responses, combined with gemcitabine and oxaliplatin chemotherapy. Used for Metastatic pancreatic cancer (in combination with gemcitabine and oxaliplatin), Advanced biliary tract cancer (in combination with gemcitabine and oxaliplatin).
At a glance
| Generic name | KN035 plus Gemcitabine & oxaliplatin |
|---|---|
| Also known as | Experimental |
| Sponsor | 3D Medicines (Sichuan) Co., Ltd. |
| Drug class | PD-L1 inhibitor |
| Target | PD-L1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
KN035 is a humanized monoclonal antibody targeting PD-L1 that prevents tumor cells from evading immune surveillance by blocking the PD-L1/PD-1 axis. When combined with gemcitabine (a nucleoside analog) and oxaliplatin (a platinum-based chemotherapy), the regimen aims to synergistically enhance anti-tumor immunity through both direct chemotherapy cytotoxicity and immune checkpoint blockade. This combination approach targets multiple mechanisms of tumor growth and immune evasion.
Approved indications
- Metastatic pancreatic cancer (in combination with gemcitabine and oxaliplatin)
- Advanced biliary tract cancer (in combination with gemcitabine and oxaliplatin)
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea and vomiting
- Fatigue
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: